Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.32 |
| ▸ | FLT3 | P36888 | 2/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31577243 | 1.00 | CCNA2 (0.35) | CCNA2CDK1CDK4CCND3CDK6 | |
| SCHEMBL31577264 | 0.88 | HRH3 (0.33) | FLT3AXL | |
| SCHEMBL31577208 | 0.88 | HRH3 (0.33) | FLT3AXL | |
| SCHEMBL31577202 | 0.88 | CDK1 (0.37) | CDK1FLT3AXL | |
| SCHEMBL24943817 | 0.84 | IKBKE (0.36) | CCNA2CDK1CDK4CCND3CDK6 | |
| SCHEMBL24944452 | 0.84 | IKBKE (0.36) | CCNA2CDK1CDK4CCND3CDK6 | |
| SCHEMBL30801807 | 0.84 | IKBKE (0.36) | CCNA2CDK1CDK4CCND3CDK6 | |
| SCHEMBL24943822 | 0.84 | IKBKE (0.36) | CCNA2CDK1CDK4CCND3CDK6 | |
| SCHEMBL31577233 | 0.82 | CCNC (0.36) | — | |
| Formic Acid SCHEMBL31195388 | 0.82 | IKBKE (0.34) | CCNA2CDK1CDK4CCND3CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | claimed |